Published :
Tables : 62
Figures : 53
Category : Healthcare
No. of Pages : 235
Report Code : HC-U3357
Branded Generics Market is predicted to value over USD xx billion by 2027 end with a CAGR of over xx% during the forecast period 2020 to 2027. Transforming medical practices, increased profit margin, entry of emerging players, simple marketing authorization processes are some of the crucial factors responsible for the growth of the market. Branded generics are wither sold by the patented drug manufacturer or by generic manufacturers building up the brand’s equity for their generic medication products. The value-added generics can either be an advanced form of dosage of a patented drug or generic drug with a name. The generics industry is booming at an exponential rate and this acceptance by pharmacy chains functioning on a large-scale which has proven to be a crucial factor for the branded generics market growth. Market Segmentation: By Product Type • Trade-Named Generics • Value-Added Branded Generics By Application • Cardiovascular Drugs • Anti-Cancer Drugs • CNS Drugs • Anti-Infective Drugs By Distribution channel • Hospital Pharmacy • Online Pharmacy • Clinics • Drug Stores By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is fragmented into product type, application, distribution channel and region. The product type segment is categorised into trade named generics, value-added branded generics. The value-added branded generics segment is anticipated to branded generics market share as they are generally developed with advanced pharma technologies. These technologies have resulted in the development of patient-friendly products that meet the bio-equivalency requirements and maintaining the same efficacy, safety and quality as the original drug. The application segment is divided into cardiovascular drugs, anti-cancer, CNS and anti-infective drugs. The cardiovascular drugs segment is predicted to lead the market owing to the expiration of many CVS drugs. The distribution channel segment is diversified into hospital pharmacy, online pharmacy, clinics and drug stores. Regional Analysis: The North America region is predicted to dominate the market during the forecast period, and this is mainly owing to rising insistence for cost-effective drugs. Generic drug supply industry is competitive in Canada over a decade. The Europe region is second to the North America region in terms of market growth owing to key players targeting European markets where the treatments are inexpensive. Competitive Landscape: Some of the prominent market players are Eva Pharmaceutical Industries Ltd, Mylan N.V., Hospira Inc., Dr. Reddy’s Laboratories Ltd., Apotex Inc., GlaxoSmithKline Pharmaceuticals Limited, Valeant, ZydusCadila, Sandoz, Lupin Pharmaceuticals Inc., Par Pharmaceutical Companies Inc., Sanofi, AstraZeneca. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global branded generics market by product type, by application, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Transforming medical practices, increased profit margin, entry of emerging players, simple marketing authorization processes are some of the crucial factors responsible for the growth of the market. Branded generics are wither sold by the patented drug manufacturer or by generic manufacturers building up the brand’s equity for their generic medication products. The value-added generics can either be an advanced form of dosage of a patented drug or generic drug with a name. The generics industry is booming at an exponential rate and this acceptance by pharmacy chains functioning on a large-scale which has proven to be a crucial factor for the branded generics market growth.
Market Segmentation:
By Product Type • Trade-Named Generics • Value-Added Branded Generics By Application • Cardiovascular Drugs • Anti-Cancer Drugs • CNS Drugs • Anti-Infective Drugs By Distribution channel • Hospital Pharmacy • Online Pharmacy • Clinics • Drug Stores By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is fragmented into product type, application, distribution channel and region. The product type segment is categorised into trade named generics, value-added branded generics. The value-added branded generics segment is anticipated to branded generics market share as they are generally developed with advanced pharma technologies. These technologies have resulted in the development of patient-friendly products that meet the bio-equivalency requirements and maintaining the same efficacy, safety and quality as the original drug. The application segment is divided into cardiovascular drugs, anti-cancer, CNS and anti-infective drugs. The cardiovascular drugs segment is predicted to lead the market owing to the expiration of many CVS drugs. The distribution channel segment is diversified into hospital pharmacy, online pharmacy, clinics and drug stores.
Regional Analysis:
The North America region is predicted to dominate the market during the forecast period, and this is mainly owing to rising insistence for cost-effective drugs. Generic drug supply industry is competitive in Canada over a decade. The Europe region is second to the North America region in terms of market growth owing to key players targeting European markets where the treatments are inexpensive.
Competitive Landscape:
Some of the prominent market players are Eva Pharmaceutical Industries Ltd, Mylan N.V., Hospira Inc., Dr. Reddy’s Laboratories Ltd., Apotex Inc., GlaxoSmithKline Pharmaceuticals Limited, Valeant, ZydusCadila, Sandoz, Lupin Pharmaceuticals Inc., Par Pharmaceutical Companies Inc., Sanofi, AstraZeneca.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global branded generics market by product type, by application, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances 5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.2 Market Restraint Analysis 5.1.3 Industry Challenges 6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape 7. Branded Generics Market, By Product Type Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 7.1 Trade-Named Generics 7.2 Value-Added Branded Generics 8. Branded Generics Market, By Application Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 8.1 Cardiovascular Drugs 8.2 Anti-Cancer Drugs 8.3 CNS Drugs 8.4 Anti-Infective Drugs 9. Branded Generics Market, By Distribution Channel Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 9.1 Hospital Pharmacy 9.2 Online Pharmacy 9.3 Clinics 9.4 Drug Stores 10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Mn) Analysis By Country, 2015-2019 10.2.1. U.S. 10.2.2. Canada 10.2.3. Mexico 10.2.4. Rest of North America 10.3 Market Size (USD Mn) Forecast for North America 2020-2027 11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 11.3.1. Brazil 11.3.2. Venezuela 11.3.3. Argentina 11.3.4. Rest of Latin America 11.4 Market Size (US$ Mn) Forecast for Latin America 2020-2027 12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5 Switzerland 12.2.6. Spain 12.2.7. Russia 12.2.8. Poland 12.2.9. Rest of Western Europe 12.3 Market Size (US$ Mn) Forecast for Europe 2020-2027 13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1 Introduction 13.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 13.2.1 Japan 13.2.2 China 13.2.3 Singapore 13.2.4 Korea 13.2.5 India 13.2.6 Australia and New Zealand 13.2.7 ASEAN 13.2.8 Rest of Asia Pacific 13.3 Market Size (US$ Mn) Forecast for Asia Pacific 2020-2027 14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1 Introduction 14.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 14.2.1 UAE 14.2.2 South Africa 14.2.3 Egypt 14.2.4 Saudi Arabia 14.2.5 Rest of MEA 14.3 Market Size (US$ Mn) Forecast for MEA 2020-2027 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 15.1 Eva Pharmaceutical Industries Ltd 15.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2 Mylan N.V. 15.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3 Hospira Inc. 15.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4 Dr. Reddy’s Laboratories Ltd. 15.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 Apotex Inc. 15.5.1. Company Overview (HQ, Business Segments, Employee Strength) 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 GlaxoSmithKline Pharmaceuticals Limited 15.6.1. Company Overview (HQ, Business Segments, Employee Strength) 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7 Valeant 15.7.1. Company Overview (HQ, Business Segments, Employee Strength) 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8 ZydusCadila 15.8.1. Company Overview (HQ, Business Segments, Employee Strength) 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9 Sandoz 15.9.1. Company Overview (HQ, Business Segments, Employee Strength) 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10 Lupin Pharmaceuticals Inc. 15.10.1. Company Overview (HQ, Business Segments, Employee Strength) 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 15.11 Par Pharmaceutical Companies Inc. 15.11.1. Company Overview (HQ, Business Segments, Employee Strength) 15.11.2. Product Portfolio 15.11.3. SWOT Analysis 15.11.4. Financial Overview 15.11.5. Strategic Overview 15.12 Sanofi 15.12.1. Company Overview (HQ, Business Segments, Employee Strength) 15.12.2. Product Portfolio 15.12.3. SWOT Analysis 15.12.4. Financial Overview 15.12.5. Strategic Overview 15.13 AstraZeneca 15.13.1. Company Overview (HQ, Business Segments, Employee Strength) 15.13.2. Product Portfolio 15.13.3. SWOT Analysis 15.13.4. Financial Overview 15.13.5. Strategic Overview 16. Impact of COVID-19 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. Competitive Intelligence and Competitive Matrix 17.1 Competitive Intelligence 17.2 Competitive Matrix 18. Major Deals and Strategic Alliances Analysis 18.1 Joint ventures 18.2 Mergers and acquisitions 18.3 Licensing and partnerships 18.4 Technology Collaborations 18.5 Strategic Divestments 18.6 Market Entry Strategies 19. Relevant Case Studies and Latest News Updates 20. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics